EUCTR2006-002524-42-IT进行中（未招募）不适用
se of mieloablative doses of zevalin in aggressive lymphomas of the elderly. Prospective randomized study Z-HDS1,2 vs R-CHOP - Z-HDS1,2 vs R-CHOP protocol
FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI0 个研究点开始时间: 2007年3月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically confirmed diagnosis of DLBCL 2. Age 65 and older, or between 60 and 65 in the presence of contraindications to high dose myeloablative chemotherapy 3. Presence of 1 or more of the following factors high LDH levels, PS 2-4, stage III-IV, 1 extranodal involvement 4. CD20 positive lymphoma 5. DLCO 50 and ejection fraction 45
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Histology other than the one described above 2. Severe concomitant or uncontrolled nonmalignant diseases 3. Presence of opportunistic infections or HIV positivity or HBsAg positivity 4. Previous or concomitant malignancies, except non-melanoma skin tumors and in situ carcinoma of the cervix 5. History of amafilaxis or serum allergic reactions 6. Unable to out-patient follow-up
研究者
相似试验
已完成
1 期
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid MalignanciesLeukemiaLymphomaNCT00048737M.D. Anderson Cancer Center70
终止
3 期
Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like TherapyDiffuse Large B-cell LymphomaFollicle Center LymphomaNCT01510184Spectrum Pharmaceuticals, Inc79
终止
2 期
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT01549886Spectrum Pharmaceuticals, Inc5
已完成
2 期
Zevalin (90Yttrium-ibritumomab tiuxetan)-BEAM and autologous stem cell transplantation or single dose 90Yttrium ibritumomab tiuxetan as consolidation of induction chemotherapy in patients with transformed non-Hodgkin*s lymphoma. ;A phase II clinical trialtransformed lymphomatransformed non-Hodgkin's lymphoma10025320NL-OMON39525Vrije Universiteit Medisch Centrum58
招募中
不适用
Zevalin-BEAM or Zevalin as consolidation in patients with transformed lymphoma.transformed B-cell non-Hodgkin's lymphomaNL-OMON21852VUmc58